Key points are not available for this paper at this time.
Incorporating ctDNA monitoring along with traditional known risk factors may aid in identifying patients with stage I EC who are at highest risk of recurrence, and possibly aid in treatment stratification.
Recio et al. (Mon,) studied this question.